Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
3,387 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07686367 | Testing the Anti-Cancer Drug, Brenetafusp (IMCF106C), in Rare Cancers | not yet recruiting | Phase 2 | 42 | National Cancer Institute (NCI)NIH | 0 | Sep 25, 2026 | clinicaltrials |
| NCT00342654 | Nutrition Intervention Trials in Linxian Follow-up Study | completed | — | 32,902 | National Cancer Institute (NCI)NIH | 1 | Sep 24, 2026 | clinicaltrials |
| NCT03191149 | Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change | recruiting | Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 | Sep 24, 2026 | clinicaltrials |
| NCT04145141 | National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer | completed | — | 132 | National Cancer Institute (NCI)NIH | 1 | Sep 24, 2026 | clinicaltrials |
| NCT04840602 | Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma | recruiting | Phase 2 | 92 | National Cancer Institute (NCI)NIH | 1 | Sep 24, 2026 | clinicaltrials |
| NCT05237934 | Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC) | recruiting | — | 300 | National Cancer Institute (NCI)NIH | 1 | Sep 24, 2026 | clinicaltrials |
| NCT05773274 | Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial | recruiting | Phase 2 | 100 | National Cancer Institute (NCI)NIH | 2 | Sep 24, 2026 | clinicaltrials |
| NCT06096844 | Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial | recruiting | Phase 3 | 304 | National Cancer Institute (NCI)NIH | 1 | Sep 24, 2026 | clinicaltrials |
| NCT06172296 | Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma | recruiting | Phase 3 | 478 | National Cancer Institute (NCI)NIH | 5 | Sep 24, 2026 | clinicaltrials |
| NCT06995872 | Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma | recruiting | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Sep 24, 2026 | clinicaltrials |
| NCT00242723 | Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining | recruiting | — | 1,559 | National Cancer Institute (NCI)NIH | 1 | Sep 23, 2026 | clinicaltrials |
| NCT02194738 | Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) | active not recruiting | N/A | 7,458 | National Cancer Institute (NCI)NIH | 3 | Sep 23, 2026 | clinicaltrials |
| NCT02392429 | FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia | active not recruiting | Phase 2 | 87 | National Cancer Institute (NCI)NIH | 1 | Sep 23, 2026 | clinicaltrials |
| NCT03816345 | Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO | recruiting | Phase 1 | 300 | National Cancer Institute (NCI)NIH | 2 | Sep 23, 2026 | clinicaltrials |
| NCT04222413 | Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors | recruiting | Phase 1 | 116 | National Cancer Institute (NCI)NIH | 1 | Sep 23, 2026 | clinicaltrials |
| NCT04301076 | Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL) | recruiting | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Sep 23, 2026 | clinicaltrials |
| NCT04729959 | Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma | active not recruiting | Phase 2 | 61 | National Cancer Institute (NCI)NIH | 1 | Sep 23, 2026 | clinicaltrials |
| NCT05333458 | Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, AXIOM Trial | recruiting | Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | Sep 23, 2026 | clinicaltrials |
| NCT05960773 | Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma | recruiting | Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06009926 | Evaluation of Broccoli Seed and Sprout Extract for Detoxification of Carcinogens in Firefighters | active not recruiting | Phase 2 | 72 | National Cancer Institute (NCI)NIH | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06102902 | Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer | recruiting | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06126276 | Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial) | recruiting | Phase 2 | 70 | National Cancer Institute (NCI)NIH | 2 | Sep 23, 2026 | clinicaltrials |
| NCT06246357 | Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisolism | recruiting | Phase 2 | 80 | National Cancer Institute (NCI)NIH | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06253520 | Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer | active not recruiting | Phase 1 | 210 | National Cancer Institute (NCI)NIH | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07012044 | A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia | recruiting | Phase 1 | 47 | National Cancer Institute (NCI)NIH | 1 | Sep 23, 2026 | clinicaltrials |
| NCT00001163 | Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Cancer | active not recruiting | — | 5,201 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT00034424 | Cause of Familial Testicular Cancer | completed | — | 749 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT00039676 | Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer | active not recruiting | — | 1,836 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT00092235 | Natural History Study of Clinical and Biological Factors Determining Outcomes in Chronic Graft-Versus-Host Disease | recruiting | — | 650 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT00339495 | Prostate Lung Colorectal and Ovarian (PLCO) Cancer Screening Trial | active not recruiting | — | 154,900 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT00339963 | Genome Expression in Lymphoma, Leukemia and Multiple Myeloma | completed | — | 1,340 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT00340405 | Development of a Biologic Specimen Bank for the Study of Early Markers of Lung Cancer Among Tin Miners in Yunnan, China | completed | — | 9,759 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT00352924 | Agriculture Health Study | active not recruiting | — | 89,655 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT00923065 | Data Collection, Clinical Care and Interventions in CCR, NCI | enrolling by invitation | — | 10,000 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT00923221 | Collection of Blood From Patients With Prostate Cancer | recruiting | — | 1,000 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT01005654 | Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms | recruiting | — | 2,415 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT01087333 | Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment | recruiting | — | 1,263 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT01174121 | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer | recruiting | Phase 2 | 332 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT01200680 | Genetic Clues to Chordoma Etiology: A Protocol to Identify Sporadic Chordoma Patients for Studies of Cancer-Susceptibility Genes | active not recruiting | — | 188 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT01443468 | Clinical and Genetic Studies of Li-Fraumeni Syndrome | recruiting | — | 5,000 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT01660984 | Natural History Study of Children and Adults With Medullary Thyroid Cancer | active not recruiting | — | 105 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT02153957 | Trial Evaluating an Enhanced Physical Activity Intervention to Improve Cognitive Late Effects in Children Treated With Cranial Radiation for Brain Tumors | completed | Phase 2 | 36 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT02314169 | Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer | active not recruiting | Phase 2 | 143 | National Cancer Institute (NCI)NIH | 2 | Sep 22, 2026 | clinicaltrials |
| NCT02423057 | Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors | completed | Phase 1 | 27 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT02484404 | Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can... | active not recruiting | Phase 1 / Phase 2 | 268 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT02544022 | Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs) | recruiting | — | 476 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT02594202 | Care of the Prostate Cancer Patient and Prospective Procurement of Prostate Cancer Tissue | recruiting | — | 3,000 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT03210714 | Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) | active not recruiting | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 2 | Sep 22, 2026 | clinicaltrials |
| NCT03226704 | Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing | enrolling by invitation | — | 120 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT03251989 | Rare CNS Tumors Outcomes &Risk | completed | — | 326 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
Data updated 5 days agoSource updated unknownsource: clinicaltrials